Carnitine, mitochondrial function and therapy

Advanced Drug Delivery Reviews

Volumn 61, Issue 14, 2009, Pages 1353-1362

  Zammit, Victor A ^a   Ramsay, Rona R ^b   Bonomini, Mario ^c   Arduini, Arduino ^d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c University Hospital of Chieti   (Italy)

^d R and D Department   (Italy)

Author keywords

Carnitine; Carnitine acyltransferases; Coenzyme A; Mitochondria

Indexed keywords

ACYL CHAIN; ACYL-COA; ACYL-COA ESTER; ACYLTRANSFERASES; BIOCHEMICAL MECHANISMS; CARNITINE; CELL FUNCTIONS; CLINICAL DATA; COENZYME A; ENZYMATIC ACTIVITIES; INTRACELLULAR COMPARTMENTS; L-CARNITINE; MITOCHONDRIAL FUNCTION; MULTIPLE EQUILIBRIUM; SIGNAL TRANSDUCTION MECHANISM;

ESTERS; MITOCHONDRIA;

SIGNAL TRANSDUCTION;

ACETYLCARNITINE; ACYL COENZYME A; ACYLCARNITINE; BEZAFIBRATE; CARNITINE; CARNITINE ACYLTRANSFERASE; PLACEBO;

CARNITINE DEFICIENCY; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; METABOLIC REGULATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARNITINE; CARNITINE ACYLTRANSFERASES; HEART DISEASES; HUMANS; MITOCHONDRIA;

EID: 71549160839     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.04.024     Document Type: Review

References (129)

1. Zammit V.A. The malonyl-CoA-long-chain acyl-CoA axis in the maintenance of mammalian cell function. Biochem. J. 343 (1999) 505-515
2. Ramsay R.R., and Tubbs P.K. The mechanism of fatty acid uptake by heart mitochondria: an acylcarnitine-carnitine exchange. FEBS Lett. 54 (1975) 21-25
3. Fraser F., Corstorphine C.G., Price N.T., and Zammit V.A. Evidence that carnitine palmitoyltransferase I (CPT I) is expressed in microsomes and peroxisomes of rat liver. Distinct immunoreactivity of the N-terminal domain of the microsomal protein. FEBS Lett. 446 (1999) 69-74
4. Zammit V.A. Carnitine acyltransferases: functional significance of subcellular distribution and membrane topology. Prog. Lipid Res. 38 (1999) 199-224
5. Turkaly P., Kerner J., and Hoppel C. A 22 kDa polyanion inhibits carnitine-dependent fatty acid oxidation in rat liver mitochondria. FEBS Lett. 460 (1999) 241-245
6. Faye A., Esnous C., Price N.T., Onfray M.A., Girard J., and Prip-Buus C. Rat liver carnitine palmitoyltransferase 1 forms an oligomeric complex within the outer mitochondrial membrane. J. Biol. Chem. 282 (2007) 26908-26916
7. Jenei Z.A., Borthwick K., Zammit V.A., and Dixon A.M. Self-association of transmembrane domain 2 (TM2), but not TM1, in carnitine palmitoyltransferase 1A: role of GXXXG(A) motifs. J. Biol. Chem. 284 (2009) 6988-6997
8. Price N., van der Leij F., Jackson V., Corstorphine C., Thomson R., Sorensen A., and Zammit V. A novel brain-expressed protein related to carnitine palmitoyltransferase I. Genomics 80 (2002) 433-442
9. Sierra A.Y., Gratacos E., Carrasco P., Clotet J., Urena J., Serra D., Asins G., Hegardt F.G., and Casals N. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J. Biol. Chem. 283 (2008) 6878-6885
10. Wolfgang M.J., Kurama T., Dai Y., Suwa A., Asaumi M., Matsumoto S., Cha S.H., Shimokawa T., and Lane M.D. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7282-7287
11. Gao X.F., Chen W., Kong X.P., Xu A.M., Wang Z.G., Sweeney G., and Wu D. Enhanced susceptibility of Cpt1c knockout mice to glucose intolerance induced by a high-fat diet involves elevated hepatic gluconeogenesis and decreased skeletal muscle glucose uptake. Diabetologia (2009)
12. Cohen I., Kohl C., McGarry J.D., Girard J., and Prip-Buus C. The N-terminal domain of rat liver carnitine palmitoyltransferase 1 mediates import into the outer mitochondrial membrane and is essential for activity and malonyl-CoA sensitivity. J. Biol. Chem. 273 (1998) 29896-29904
13. Gooding J.M., Shayeghi M., and Saggerson E.D. Membrane transport of fatty acylcarnitine and free l-carnitine by rat liver microsomes. Eur. J. Biochem. 271 (2004) 954-961
14. Abo-Hashema K.A., Cake M.H., Power G.W., and Clarke D. Evidence for triacylglycerol synthesis in the lumen of microsomes via a lipolysis-esterification pathway involving carnitine acyltransferases. J. Biol. Chem. 274 (1999) 35577-35582
15. Owen M.R., Corstorphine C.C., and Zammit V.A. Overt and latent activities of diacylglycerol acytransferase in rat liver microsomes: possible roles in very-low-density lipoprotein triacylglycerol secretion. Biochem. J. 323 (1997) 17-21
16. Fraser F., and Zammit V.A. Enrichment of carnitine palmitoyltransferases I and II in the contact sites of rat liver mitochondria. Biochem. J. 329 (1998) 225-229
17. Ramsay R.R., and Zammit V.A. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol. Aspects Med. 25 (2004) 475-493
18. Westin M.A., Hunt M.C., and Alexson S.E. Short- and medium-chain carnitine acyltransferases and acyl-CoA thioesterases in mouse provide complementary systems for transport of beta-oxidation products out of peroxisomes. Cell. Mol. Life Sci. 65 (2008) 982-990
19. Cordente A.G., Lopez-Vinas E., Vazquez M.I., Swiegers J.H., Pretorius I.S., Gomez-Puertas P., Hegardt F.G., Asins G., and Serra D. Redesign of carnitine acetyltransferase specificity by protein engineering. J. Biol. Chem. 279 (2004) 33899-33908
20. Jogl G., Hsiao Y.S., and Tong L. Crystal structure of mouse carnitine octanoyltransferase and molecular determinants of substrate selectivity. J. Biol. Chem. 280 (2005) 738-744
21. Jogl G., and Tong L. Crystal structure of carnitine acetyltransferase and implications for the catalytic mechanism and fatty acid transport. Cell 112 (2003) 113-122
22. Cordente A.G., Lopez-Vinas E., Vazquez M.I., Gomez-Puertas P., Asins G., Serra D., and Hegardt F.G. Mutagenesis of specific amino acids converts carnitine acetyltransferase into carnitine palmitoyltransferase. Biochemistry 45 (2006) 6133-6141
23. Sitheswaran N., Price N.T., and Ramsay R.R. The G553M mutant of peroxisomal carnitine octanoyltransferase catalyses acetyl transfer and acetyl-CoA hydrolysis. Monatsh. Chem. - Chemical Monthly 136 (2005) 1341-1347
24. Vessey D.A., Chen W.W., and Ramsay R.R. Effect of carboxylic acid xenobiotics and their metabolites on the activity of carnitine acyltransferases. Biochem. J. 279 (1991) 895-897
25. Mitchell G.A., Gauthier N., Lesimple A., Wang S.P., Mamer O., and Qureshi I. Hereditary and acquired diseases of acyl-coenzyme A metabolism. Mol. Genet. Metab. 94 (2008) 4-15
26. Corti O., DiDonato S., and Finocchiaro G. Divergent sequences in the 5′ region of cDNA suggest alternative splicing as a mechanism for the generation of carnitine acetyltransferases with different subcellular localizations. Biochem. J. 303 (1994) 37-41
27. Verhoeven N.M., Roe D.S., Kok R.M., Wanders R.J., Jakobs C., and Roe C.R. Phytanic acid and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J. Lipid Res. 39 (1998) 66-74
28. Brady P.S., Marine K.A., Brady L.J., and Ramsay R.R. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochem. J. 260 (1989) 93-100
29. Ramsay R.R., Gandour R.D., and van der Leij F.R. Molecular enzymology of carnitine transfer and transport. Biochim. Biophys. Acta 1546 (2001) 21-43
30. van der Leij F.R., Huijkman N.C., Boomsma C., Kuipers J.R., and Bartelds B. Genomics of the human carnitine acyltransferase genes. Mol. Genet. Metab. 71 (2000) 139-153
31. Desiderio C., Mancinelli A., De Rossi A., Rossetti D.V., Inzitari R., Messana I., Giardina B., and Castagnola M. Rapid determination of short chain carnitines in human plasma by electrospray ionisation-ion trap mass spectrometry using capillary electrophoresis instrument as sampler. J. Chromatogr. A 1150 (2007) 320-326
32. Minkler P.E., Stoll M.S., Ingalls S.T., Yang S., Kerner J., and Hoppel C.L. Quantification of carnitine and acylcarnitines in biological matrices by HPLC electrospray ionization-mass spectrometry. Clin. Chem. 54 (2008) 1451-1462
33. Bhuiyan A.K., Bartlett K., Sherratt H.S., and Agius L. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity. Biochem. J. 253 (1988) 337-343
34. Nezu J., Tamai I., Oku A., Ohashi R., Yabuuchi H., Hashimoto N., Nikaido H., Sai Y., Koizumi A., Shoji Y., Takada G., Matsuishi T., Yoshino M., Kato H., Ohura T., Tsujimoto G., Hayakawa J., Shimane M., and Tsuji A. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat. Genet. 21 (1999) 91-94
35. Reuter S.E., Evans A.M., Chace D.H., and Fornasini G. Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann. Clin. Biochem. 45 (2008) 585-592
36. Amat di San Filippo C., Taylor M.R., Mestroni L., Botto L.D., and Longo N. Cardiomyopathy and carnitine deficiency. Mol. Genet. Metab. 94 (2008) 162-166
37. Lysiak W., Lilly K., DiLisa F., Toth P.P., and Bieber L.L. Quantitation of the effect of l-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J. Biol. Chem. 263 (1988) 1151-1156
38. Rubio-Gozalbo M.E., Bakker J.A., Waterham H.R., and Wanders R.J. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol. Aspects Med. 25 (2004) 521-532
39. Iacobazzi V., Pasquali M., Singh R., Matern D., Rinaldo P., Amat di San Filippo C., Palmieri F., and Longo N. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am. J. Med. Genet. 126A (2004) 150-155
40. Brass E.P., and Hoppel C.L. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem. J. 190 (1980) 495-504
41. Huang H., Atshaves B.P., Frolov A., Kier A.B., and Schroeder F. Acyl-coenzyme A binding protein expression alters liver fatty acyl-coenzyme A metabolism. Biochemistry 44 (2005) 10282-10297
42. Fraser F., Corstorphine C.G., and Zammit V.A. Topology of carnitine palmitoyltransferase I in the mitochondrial outer membrane. Biochem. J. 323 (1997) 711-718
43. Ji S., You Y., Kerner J., Hoppel C.L., Schoeb T.R., Chick W.S., Hamm D.A., Sharer J.D., and Wood P.A. Homozygous carnitine palmitoyltransferase 1b (muscle isoform) deficiency is lethal in the mouse. Mol. Genet. Metab. 93 (2008) 314-322
44. Nyman L.R., Cox K.B., Hoppel C.L., Kerner J., Barnoski B.L., Hamm D.A., Tian L., Schoeb T.R., and Wood P.A. Homozygous carnitine palmitoyltransferase 1a (liver isoform) deficiency is lethal in the mouse. Mol. Genet. Metab. 86 (2005) 179-187
45. Invernizzi F., Burlina A.B., Donadio A., Giordano G., Taroni F., and Garavaglia B. Lethal neonatal presentation of carnitine palmitoyltransferase I deficiency. J. Inherit. Metab. Dis. 24 (2001) 601-602
46. Brown N.F., Mullur R.S., Subramanian I., Esser V., Bennett M.J., Saudubray J.M., Feigenbaum A.S., Kobari J.A., Macleod P.M., McGarry J.D., and Cohen J.C. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J. Lipid Res. 42 (2001) 1134-1142
47. Ijlst I., Mandel H., Oostheim W., Ruiter J.P., Gutman A., and Wanders R.J. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. J. Clin. Invest. 102 (1998) 527-531
48. Bennett M.J., Boriack R.L., Narayan S., Rutledge S.L., and Raff M.L. Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol. Genet. Metab. 82 (2004) 59-63
49. Morillas M., Lopez-Vinas E., Valencia A., Serra D., Gomez-Puertas P., Hegardt F.G., and Asins G. Structural model of carnitine palmitoyltransferase I based on the carnitine acetyltransferase crystal. Biochem. J. 379 (2004) 777-784
50. Gobin S., Thuillier L., Jogl G., Faye A., Tong L., Chi M., Bonnefont J.P., Girard J., and Prip-Buus C. Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J. Biol. Chem. 278 (2003) 50428-50434
51. Greenberg C.R., Dilling L.A., Thompson G.R., Seargeant L.E., Haworth J.C., Phillips S., Chan A., Vallance H.D., Waters P.J., Sinclair G., Lillquist Y., Wanders R.J., and Olpin S.E. The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populations. Mol. Genet. Metab. 96 (2009) 201-207
52. Eaton S., Bartlett K., and Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem. J. 320 (1996) 345-357
53. Isackson P.J., Bennett M.J., Lichter-Konecki U., Willis M., Nyhan W.L., Sutton V.R., Tein I., and Vladutiu G.D. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol. Genet. Metab. 94 (2008) 422-427
54. Haap M., Thamer C., Machann J., Tschritter O., Loblein K., Kellerer M., Schick F., Jacob S., Haring H.U., and Stumvoll M. Metabolic characterization of a woman homozygous for the Ser113Leu missense mutation in carnitine palmitoyl transferase II. J. Clin. Endocrinol. Metab. 87 (2002) 2139-2143
55. Djouadi F., Aubey F., Schlemmer D., and Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J. Clin. Endocrinol. Metab. 90 (2005) 1791-1797
56. Brady L.J., Ramsay R.R., and Brady P.S. Regulation of carnitine acyltransferase synthesis in lean and obese Zucker rats by dehydroepiandrosterone and clofibrate. J. Nutr. 121 (1991) 525-531
57. Luci S., Hirche F., and Eder K. Fasting and caloric restriction increases mRNA concentrations of novel organic cation transporter-2 and carnitine concentrations in rat tissues. Ann. Nutr. Metab. 52 (2008) 58-67
58. Makowski L., Noland R.C., Koves T.R., Xing W., Ilkayeva O.R., Muehlbauer M.J., Stevens R.D., and Muoio D.M. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J. 23 (2009) 586-604
59. Roe C.R., Yang B.Z., Brunengraber H., Roe D.S., Wallace M., and Garritson B.K. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 71 (2008) 260-264
60. Arduini A., Bonomini M., Savica V., Amato A., and Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol. Ther. 120 (2008) 149-156
61. Evans J.D., Jacobs T.F., and Evans E.W. Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy. Ann. Pharmacother. 42 (2008) 1686-1691
62. Ferrari R., Merli E., Cicchitelli G., Mele D., Fucili A., and Ceconi C. Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann. N. Y. Acad. Sci. 1033 (2004) 79-91
63. Handelman G.J. Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy. Blood Purif. 24 (2006) 140-142
64. Hedayati S.S. Dialysis-related carnitine disorder. Semin. Dial 19 (2006) 323-328
65. Lynch K.E., Feldman H.I., Berlin J.A., Flory J., Rowan C.G., and Brunelli S.M. Effects of l-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. Am. J. Kidney Dis. 52 (2008) 962-971
66. Schreiber B.D. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients. Blood Purif. 24 (2006) 128-139
67. Winter S.C. Treatment of carnitine deficiency. J. Inherit. Metab. Dis. 26 (2003) 171-180
68. den Boer M.E., Wanders R.J., Morris A.A., IJlst L., Heymans H.S., and Wijburg F.A. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 109 (2002) 99-104
69. Steinman T.I. l-Carnitine supplementation in dialysis patients: does the evidence justify its use?. Semin. Dial 18 (2005) 1-2
70. Jitrapakdee S., Vidal-Puig A., and Wallace J.C. Anaplerotic roles of pyruvate carboxylase in mammalian tissues. Cell. Mol. Life Sci. 63 (2006) 843-854
71. Wahren J., and Ekberg K. Splanchnic regulation of glucose production. Annu. Rev. Nutr. 27 (2007) 329-345
72. Jitrapakdee S., and Wallace J.C. Structure, function and regulation of pyruvate carboxylase. Biochem. J. 340 Pt 1 (1999) 1-16
73. Jin E.S., Jones J.G., Merritt M., Burgess S.C., Malloy C.R., and Sherry A.D. Glucose production, gluconeogenesis, and hepatic tricarboxylic acid cycle fluxes measured by nuclear magnetic resonance analysis of a single glucose derivative. Anal. Biochem. 327 (2004) 149-155
74. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14 (1998) 263-283
75. Roche T.E., and Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell. Mol. Life Sci. 64 (2007) 830-849
76. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131 (1999) 281-303
77. Kelley D.E., and Mandarino L.J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49 (2000) 677-683
78. Wu P., Inskeep K., Bowker-Kinley M.M., Popov K.M., and Harris R.A. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 48 (1999) 1593-1599
79. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005) 1093-1129
80. Dyck J.R., Hopkins T.A., Bonnet S., Michelakis E.D., Young M.E., Watanabe M., Kawase Y., Jishage K., and Lopaschuk G.D. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 114 (2006) 1721-1728
81. Ferdinandy P., Schulz R., and Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 59 (2007) 418-458
82. Stanley W.C., Lopaschuk G.D., Hall J.L., and McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res. 33 (1997) 243-257
83. Kassiotis C., Rajabi M., and Taegtmeyer H. Metabolic reserve of the heart: the forgotten link between contraction and coronary flow. Prog. Cardiovasc. Dis. 51 (2008) 74-88
84. Caspi L., Wang P.Y., and Lam T.K. A balance of lipid-sensing mechanisms in the brain and liver. Cell Metab. 6 (2007) 99-104
85. Gao Q., and Horvath T.L. Neuronal control of energy homeostasis. FEBS Lett. 582 (2008) 132-141
86. Obici S., Feng Z., Morgan K., Stein D., Karkanias G., and Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51 (2002) 271-275
87. He W., Lam T.K., Obici S., and Rossetti L. Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat. Neurosci. 9 (2006) 227-233
88. Obici S., Feng Z., Arduini A., Conti R., and Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat. Med. 9 (2003) 756-761
89. Pocai A., Lam T.K., Obici S., Gutierrez-Juarez R., Muse E.D., Arduini A., and Rossetti L. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J. Clin. Invest. 116 (2006) 1081-1091
90. Lam T.K., Gutierrez-Juarez R., Pocai A., and Rossetti L. Regulation of blood glucose by hypothalamic pyruvate metabolism. Science 309 (2005) 943-947
91. Deems R.O., Anderson R.C., and Foley J.E. Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am. J. Physiol. 274 (1998) R524-R528
92. Du X., Edelstein D., Obici S., Higham N., Zou M.H., and Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J. Clin. Invest. 116 (2006) 1071-1080
93. Mayers R.M., Leighton B., and Kilgour E. PDH kinase inhibitors: a novel therapy for type II diabetes?. Biochem. Soc. Trans. 33 (2005) 367-370
94. Stacpoole P.W., Henderson G.N., Yan Z., Cornett R., and James M.O. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab. Rev. 30 (1998) 499-539
95. Sharma N., Okere I.C., Brunengraber D.Z., McElfresh T.A., King K.L., Sterk J.P., Huang H., Chandler M.P., and Stanley W.C. Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation. J. Physiol. 562 (2005) 593-603
96. Smolenski R.T., Amrani M., Jayakumar J., Jagodzinski P., Gray C.C., Goodwin A.T., Sammut I.A., and Yacoub M.H. Pyruvate/dichloroacetate supply during reperfusion accelerates recovery of cardiac energetics and improves mechanical function following cardioplegic arrest. Eur. J. Cardiothorac. Surg. 19 (2001) 865-872
97. Turcani M., and Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96 (1997) 3681-3686
98. Tuunanen H., Engblom E., Naum A., Nagren K., Scheinin M., Hesse B., Juhani Airaksinen K.E., Nuutila P., Iozzo P., Ukkonen H., Opie L.H., and Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 (2008) 1250-1258
99. Ferrannini E., Buzzigoli G., Bevilacqua S., Boni C., Del Chiaro D., Oleggini M., Brandi L., and Maccari F. Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am. J. Physiol. 255 (1988) E946-E952
100. Capaldo B., Napoli R., Di Bonito P., Albano G., and Sacca L. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Pract. 14 (1991) 191-195
101. Mingrone G., Greco A.V., Capristo E., Benedetti G., Giancaterini A., De Gaetano A., and Gasbarrini G. l-Carnitine improves glucose disposal in type 2 diabetic patients. J. Am. Coll. Nutr. 18 (1999) 77-82
102. Biolo G., Stulle M., Bianco F., Mengozzi G., Barazzoni R., Vasile A., Panzetta G., and Guarnieri G. Insulin action on glucose and protein metabolism during l-carnitine supplementation in maintenance haemodialysis patients. Nephrol. Dial. Transplant. 23 (2008) 991-997
103. De Gaetano A., Mingrone G., Castagneto M., and Calvani M. Carnitine increases glucose disposal in humans. J. Am. Coll. Nutr. 18 (1999) 289-295
104. Gonzalez-Ortiz M., Hernandez-Gonzalez S.O., Hernandez-Salazar E., and Martinez-Abundis E. Effect of oral l-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Ann. Nutr. Metab. 52 (2008) 335-338
105. Arenas J., Huertas R., Campos Y., Diaz A.E., Villalon J.M., and Vilas E. Effects of l-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett. 341 (1994) 91-93
106. Uziel G., Garavaglia B., and Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve 11 (1988) 720-724
107. Stephens F.B., Constantin-Teodosiu D., Laithwaite D., Simpson E.J., and Greenhaff P.L. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J. Clin. Endocrinol. Metab. 91 (2006) 5013-5018
108. Rodrigues B., Xiang H., and McNeill J.H. Effect of l-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37 (1988) 1358-1364
109. Rajasekar P., and Anuradha C.V. Fructose-induced hepatic gluconeogenesis: effect of l-carnitine. Life Sci. 80 (2007) 1176-1183
110. Power R.A., Hulver M.W., Zhang J.Y., Dubois J., Marchand R.M., Ilkayeva O., Muoio D.M., and Mynatt R.L. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 50 (2007) 824-832
111. Liedtke A.J., and Nellis S.H. Effects of carnitine in ischemic and fatty acid supplemented swine hearts. J. Clin. Invest. 64 (1979) 440-447
112. Broderick T.L., Quinney H.A., and Lopaschuk G.D. l-Carnitine increases glucose metabolism and mechanical function following ischaemia in diabetic rat heart. Cardiovasc. Res. 29 (1995) 373-378
113. Martin M.A., Gomez M.A., Guillen F., Bornstein B., Campos Y., Rubio J.C., de la Calzada C.S., and Arenas J. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim. Biophys. Acta 1502 (2000) 330-336
114. Broderick T.L. Hypocarnitinaemia induced by sodium pivalate in the rat is associated with left ventricular dysfunction and impaired energy metabolism. Drugs R & D 7 (2006) 153-161
115. Broderick T.L., Quinney H.A., and Lopaschuk G.D. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J. Biol. Chem. 267 (1992) 3758-3763
116. Broderick T.L., Quinney H.A., Barker C.C., and Lopaschuk G.D. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 87 (1993) 972-981
117. Loster H., Keller T., Grommisch J., and Grunder W. Effects of l-carnitine and its acetyl and propionyl esters on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 31P-NMR spectroscopy. Mol. Cell. Biochem. 200 (1999) 93-102
118. Davini P., Bigalli A., Lamanna F., and Boem A. Controlled study on l-carnitine therapeutic efficacy in post-infarction. Drugs Exp. Clin. Res. 18 (1992) 355-365
119. Iliceto S., Scrutinio D., Bruzzi P., D'Ambrosio G., Boni L., Di Biase M., Biasco G., Hugenholtz P.G., and Rizzon P. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 26 (1995) 380-387
120. Sakurabayashi T., Miyazaki S., Yuasa Y., Sakai S., Suzuki M., Takahashi S., and Hirasawa Y. l-Carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis. Circ. J. 72 (2008) 926-931
121. Tarantini G., Scrutinio D., Bruzzi P., Boni L., Rizzon P., and Iliceto S. Metabolic treatment with l-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 106 (2006) 215-223
122. Demeyere R., Lormans P., Weidler B., Minten J., Van Aken H., and Flameng W. Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind, randomized, placebo-controlled clinical trial. Anesth. Analg. 71 (1990) 520-528
123. Fagher B., Cederblad G., Monti M., Olsson L., Rasmussen B., and Thysell H. Carnitine and left ventricular function in haemodialysis patients. Scand. J. Clin. Lab. Invest. 45 (1985) 193-198
124. Evans A.M., and Fornasini G. Pharmacokinetics of l-carnitine. Clin. Pharmacokinet. 42 (2003) 941-967
125. Tein I. Carnitine transport: pathophysiology and metabolism of known molecular defects. J. Inherit. Metab. Dis. 26 (2003) 147-169
126. Rebouche C.J. Carnitine function and requirements during the life cycle. FASEB J. 6 (1992) 3379-3386
127. Hurot J.M., Cucherat M., Haugh M., and Fouque D. Effects of l-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J. Am. Soc. Nephrol. 13 (2002) 708-714
128. Kazmi W.H., Obrador G.T., Sternberg M., Lindberg J., Schreiber B., Lewis V., and Pereira B.J. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am. J. Nephrol. 25 (2005) 106-115
129. Schreiber B. Levocarnitine and dialysis: a review. Nutr. Clin. Pract. 20 (2005) 218-243